A review highlights how targeting altered lipid metabolism in pancreatic ductal adenocarcinoma can reshape the immunosuppressive microenvironment and enhance sensitivity ...
A comprehensive review analyzes how dynamic urothelial barrier conditions dictate retention, repair, and tissue navigation for intravesical biomaterial drug delivery.
A systematic review of 48 preclinical investigations demonstrates that gold nanoparticle-based nanocarriers improve targeted drug delivery and reduce toxicity toward ...
In vitro tests demonstrate that engineered lectin-conjugated liposomes selectively bind high-mannose bladder cancer cells and boost gemcitabine cytotoxicity under simulated ...
Researchers discover that inhibiting the splicing regulator SRRM1 activates ferroptosis to overcome gemcitabine resistance in pancreatic cancer models.
A review highlights Histone Deacetylase 1 as a promising epigenetic target to address drug resistance and poor prognosis in cholangiocarcinoma.
Laboratory experiments show collagen type I coating inhibits pancreatic cancer cell growth while fibronectin supports it, and both reduce sensitivity ...
A single-cell study of pretreatment nasopharyngeal carcinoma biopsies identifies an SPP1-CD44 macrophage-tumor communication axis linked to chemotherapy tolerance.
Preclinical work shows the pan-RAS inhibitor RMC-6236 triggers adaptive EGFR feedback in KRAS-mutant cholangiocarcinoma cells, and pairing it with cetuximab ...
An updated systematic review of 12 studies in 1,248 patients finds sequential intravesical gemcitabine plus docetaxel offers durable disease control ...
A retrospective Chinese study reports that all 11 patients with lymph-node-dominant metastatic gallbladder cancer responded to PD-1 blockade plus gemcitabine ...
A gemcitabine-modified tumor-suppressor microRNA called Gem-miR-15a overcame 5-FU and oxaliplatin resistance in preclinical colorectal cancer models with low-nanomolar potency and ...
A combined genetic, cellular, and mouse study finds that semaglutide strengthens gemcitabine's antitumor effect by suppressing RRM1 while weakening methotrexate ...
A prospective phase II pilot study from non-endemic Sichuan reports 95.2 percent response rates and 80 percent event-free survival at ...
A retrospective study of 313 patients found that baseline renal impairment doubled the risk of rash during gemcitabine plus nab-paclitaxel ...
Three-year follow-up of the phase 3 KEYNOTE-966 trial confirms that adding pembrolizumab to gemcitabine and cisplatin chemotherapy maintains a durable ...
A systematic review of five real-world studies finds that a biweekly gemcitabine and nab-paclitaxel schedule matches standard survival outcomes in ...
In a groundbreaking advance that could reshape the therapeutic landscape of pancreatic ductal adenocarcinoma (PDAC), researchers have unveiled how the ...
